Catalyst
Monitor further results from this trial and similar studies, especially regarding clinical outcomes and regulatory interest in FMT for sepsis.
Humanexa recommends Monitor.
Date
July 11, 2026
Phase
N/A
Status
watch
Signal score
7.0
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.